MORTALITY IN PROXIMAL FEMUR FRACTURES IN AN OLD-AGE GROUP OF KEMEROVO AS A RATIONALE FOR THE NECESSITYOF MEDICAL PREVENTION OF OSTEOPOROSIS
https://doi.org/10.14412/1996-7012-2011-650
Abstract
Objective: to study mortality rates in proximal femur fractures in an old-age group of Kemerovo after 6, 12, and 24 months.
Subjects and methods. Mortality rates were analyzed in 432 patients (328 women and 104 men) after osteoporotic fractures with the minimum
amount of trauma injury, sustained in January 2004 to December 2008. The rates were followed up at 0-6, 6-12, and 12-24 months.
Results. Ninety-five (22.0%) of the 432 patients died in the first 6 months of injury; 42 (12.5%) patients of 337 patients died at 6-12 months, and 47 (16.2%) patients of the remaining 290 followed-up survivors died at 12-24 months. In the first 6 months, the mortality rates were found
to be significantly higher than those in the following 6-12 (p<0.0001) and 12-24 (p<0.05) months.
Conclusion. Osteoporotic fractures of the proximal femur are characterized by the high mortality rates reaching the maximum in the first 12
months following fracture.
Subjects and methods. Mortality rates were analyzed in 432 patients (328 women and 104 men) after osteoporotic fractures with the minimum
amount of trauma injury, sustained in January 2004 to December 2008. The rates were followed up at 0-6, 6-12, and 12-24 months.
Results. Ninety-five (22.0%) of the 432 patients died in the first 6 months of injury; 42 (12.5%) patients of 337 patients died at 6-12 months, and 47 (16.2%) patients of the remaining 290 followed-up survivors died at 12-24 months. In the first 6 months, the mortality rates were found
to be significantly higher than those in the following 6-12 (p<0.0001) and 12-24 (p<0.05) months.
Conclusion. Osteoporotic fractures of the proximal femur are characterized by the high mortality rates reaching the maximum in the first 12
months following fracture.
About the Authors
Tat'yana Alekseevna RaskinaYu V Averkieva
Tatyana Alekseyevna Raskina
Yu V Averkieva
References
1. <div><p>Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. Рук-во по остеопорозу. М.: Бином, 2003;10-53.</p><p>Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии 2002;1:8-11.</p><p>Михайлов Е.Е., Меньшикова Л.В., Ершова О.Б. Эпидемиология остеопороза и переломов в России. Остеопороз и остеопатии (прил.) 2003;44.</p><p>Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение: Клинические рекомендации. М.: ГЭОТАР-Медиа, 2005;176.</p><p>Black D.M., Steinbuch M., Palermo I. An assessment tool for predicting fracture risk in postmenopausal woman. Osteoporosis Int 2001;12:519-28.</p><p>Rochira V., Balestrieri A., Madeo B. et al. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur J Endocrinol 2006;154(2):175-85.</p><p>Binkley N. Osteoporosis in men. Arq Bras Endocrinol Metab 2006;50(4):764-74.</p><p>Khan A.A., Hodsman A.B., Papaioannou A. et al. Management of osteoporosis in men: an update and case example CMAJ 2007; 176(3):345-8.</p><p>Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза. Рук-во по остеопорозу. М.: Бином, 2003;469-81.</p><p>O'Neill T.W., Cooper C., Finn J.D. et al. Incidence of distal forearm fracture in British men and woman. Osteoporosis Int 2002;(12):555-58.</p><p>Kanis J.A., Oden A., Johnell O. et al. The use of clinical risk factors 2007 enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;7:1033-46.</p><p>US Department of Health and Human Services (DHHS). Report of the surgeon general's workshop on osteoporosis and bone health, 2006;1-100. Available at http://www.surgeongeneral.gov/library/bonehealthindex.html. Accessed 11 Dec 2009.</p><p>Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-S9.</p><p>Oden A., Dawson A., Dere W. et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603.</p><p>Van Schoor N.M., Smit J.M., Twisk J.W. et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 2003;289:1957-62.</p><p>Grant A.M., Avenell A., Campbell M.K. et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, RECORD): a randomized placebo-controlled trial. Lancet 2005;365:1621-8.</p><p>Jackson R.D., LaCroix A.Z., Gass M. et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.</p><p>Kanis J.A., Burlet N., Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.</p><p>Alonso-Coello P., Garcia-Franco A.L., Guyatt G. et al. Drugs for preosteoporosis: prevention or disease mongering. BMJ 2008;336:126-9.</p><p>Barratt A., Wyer P.C., Hatala R. et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.</p><p>Replogle W.H., Johnson W.D. Interpretation of absolute measures of disease risk in comparative research. Fam Med 2007;39:432-5.</p><p>Ringe J.D., Doherty J.G. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010;30:863-9. DOI 10.1007/s00296-009-1311-y.</p><p>Kanis J.A., Johnell O., Black D.M. et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 2003;33:293-300.</p><p>Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.</p><p>Black D.M., Cummings S.R., Karpf D.B. et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.</p><p>Chesnut C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.</p><p>Harris S.T., Watts N.B., Genant H.K. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.</p><p>Ettinger B., Black D.M., Mitlak B.H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.</p><p>McClung M.R., Geusens P., Miller P.D. et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.</p><p>Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.</p><p>Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.</p><p>Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.</p><p>Agence Francaise de Securite Sanitaire des Produits Traitement de l'osteoporose post-menopausique, 2006. http://afssaps.sante.fr/pdf/5/rbp/ostemarg.pdf. Accessed 9 Oct 2009.</p><p>Committee for Medicinal Products for Human Use (CHMP). Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use, 2007. http://www.emea.europa.eu/pdfs/human/br methods/1540407en.pdf. Accessed 9 Oct 2009.</p><p>MacLaughlin E.J., Raehl C.L. ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. Am J Health Syst Pharm 2008;65:343-57.</p><p>Reginster J.Y., Felsenberg D., Boonen S. et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthr Rheum 2008;58:1687-95.</p></div><br />
Review
For citations:
Raskina TA, Averkieva YV, Raskina TA, Averkieva YV. MORTALITY IN PROXIMAL FEMUR FRACTURES IN AN OLD-AGE GROUP OF KEMEROVO AS A RATIONALE FOR THE NECESSITYOF MEDICAL PREVENTION OF OSTEOPOROSIS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2011;5(1):39-46. (In Russ.) https://doi.org/10.14412/1996-7012-2011-650
Views:
1108
Email this article 